| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
Rigel Pharmaceuticals (NASDAQ:RIGL) reported its Q4 earnings results on Tuesday, March 5, 2024 at 04:01 PM.
Here's what investors need to know about the announcement.
Rigel Pharmaceuticals beat estimated earnings by 100.0%, reporting an EPS of $0.0 versus an estimate of $-0.03.
Revenue was down $15.49 million from the same period last year.
Last quarter the company beat on EPS by $0.04 which was followed by a 2.0% increase in the share price the next day.
Here's a look at Rigel Pharmaceuticals's past performance:
| Quarter | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 |
|---|---|---|---|---|
| EPS Estimate | -0.07 | -0.08 | -0.10 | -0.11 |
| EPS Actual | -0.03 | -0.04 | -0.08 | 0.01 |
| Revenue Estimate | 27.20M | 26.02M | 24.07M | 27.97M |
| Revenue Actual | 28.13M | 26.89M | 26.07M | 51.28M |
To track all earnings releases for Rigel Pharmaceuticals visit their earnings calendar here.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Posted In: RIGL
